共 101 条
[1]
Shrestha SS(2019)Factors contributing to increases in diabetes-related preventable hospitalization costs among U.S. Adults during 2001–2014 Diabetes Care 42 77-84
[2]
Zhang P(2019)Dapagliflozin and cardiovascular outcomes in type 2 diabetes N Engl J Med 380 347-357
[3]
Hora I(2020)Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial Lancet Diabetes Endocrinol 8 949-959
[4]
Geiss LS(2023)Empagliflozin in patients with chronic kidney disease N Engl J Med 388 117-127
[5]
Luman ET(2023)Effects of dapagliflozin on hospitalizations in patients with chronic kidney disease : a post hoc analysis of DAPA-CKD Ann Intern Med 176 59-66
[6]
Gregg EW(2021)Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: a secondary analysis Diabetes Obes Metab 23 2707-2715
[7]
Wiviott SD(2021)Association of diabetes with frequency and cost of hospital admissions: a retrospective cohort study CMAJ Open 9 E406-E412
[8]
Raz I(undefined)undefined undefined undefined undefined-undefined
[9]
Bonaca MP(undefined)undefined undefined undefined undefined-undefined
[10]
Mosenzon O(undefined)undefined undefined undefined undefined-undefined